Kyverna Therapeutics Inc (KYTX) Stock Price, Quote & News

Company Profile

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product cand...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 925 2492

Website: kyvernatx.com

Address:

5980 Horton Street, Suite 550, Emeryville, United States

ak123456790 May. 13 at 7:34 AM

$KYTX Fair value right now is 18-25.. The company is totally de risked and they will get approved next year! I don't know the big funds why they haven't found that gem yet, but they will soon ! Then they will pay a premium for being late.. I believe the BO will happen before the FDA approval around q1-q2 2027.. Otherwise later it becomes more expensive ! Whatever the future brings, this stock is to hold strong until the end of it's journey ! Best in class drugs, cheap stock price, no competition.. what else to ask !

0 · Reply

Th3M4skedSt0nker May. 12 at 10:51 PM

$KYTX

0 · Reply

hummer2277 May. 12 at 10:26 PM

$KYTX more funds will start moving in as time goes on , buy and hold, already large institutional amount of investors.

0 · Reply

Salattis May. 12 at 8:12 PM

$KYTX https://www.globenewswire.com/news-release/2026/05/12/3293353/0/en/Kyverna-Therapeutics-Announces-Initiation-of-Rolling-SPS-BLA-Submission-and-Reports-First-Quarter-2026-Financial-Results.html

1 · Reply

AlphaOfBiotech May. 12 at 5:13 AM

$FATE had successfully treated 8+ patients in Regimen A (Less-Intensive Chemo). The outcomes here were spectacular, with patients achieving complete drug-free remissions (cures). The 100% response rate (3 out of 3) today on the first 3 patients from Regimen B (No Chemo / Background Therapy) is an absolute clinical triumph as proof of concept. With DL1 achieved a 100% response without chemo and the Phase 2 pivotal trial clearance by the FDA, hold strong and you will get rewarded. GO GO GO $FATE $ALLO $CABA $KYTX $LABU

1 · Reply

AlphaOfBiotech May. 12 at 3:51 AM

$FATE The fact that B-cell depletion lasted 12 months and occurred in secondary lymphoid tissue (nasopharyngeal) is a signature of CAR-T activity, not background steroids. The FDA's selection of Fate for the CDRP pilot suggests they are satisfied that the signal is coming from FT819, not the background drugs. Hope the management will announce that the RECLAIM-LN Phase 2 will be chemo-free and, most importantly, a registrational pivotal trial tomorrow. Cheers! $FATE $ALLO $CABA $KYTX

0 · Reply

InsaneZane May. 11 at 9:17 PM

$KYTX could this turn into a 2 day bull run?

0 · Reply

cb28 May. 11 at 6:09 PM

$KYTX why is this up today?

2 · Reply

peapope May. 11 at 3:07 PM

$KYTX first public Car-T to FDA approval!

0 · Reply

Th3M4skedSt0nker May. 11 at 2:50 PM

$KYTX I raise to $11 by end of this week 💲🔥💲🔥💲

0 · Reply

Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan

2026-05-12T22:38:44.000Z - 14 hours ago

Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)

May 12, 2026, 4:02 PM EDT - 16 hours ago

Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results

2026-05-04T12:45:05.000Z - 8 days ago

Kyverna Therapeutics appoints Nadia Dac as chief commercial officer

OMER

May 4, 2026, 8:00 AM EDT - 9 days ago

Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer

Apr 22, 2026, 7:00 AM EDT - 21 days ago

Kyverna Therapeutics Transcript: Status update

2026-04-21T22:50:16.000Z - 21 days ago

Kyverna Therapeutics reports ‘positive’ results from KYSA-8 trial of miv-cel

Apr 21, 2026, 6:45 PM EDT - 21 days ago

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

2026-04-20T13:12:24.000Z - 22 days ago

Kyverna Therapeutics presents longer-term Phase 2 data for Miv-cel

Apr 20, 2026, 8:00 AM EDT - 23 days ago

Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

Apr 9, 2026, 8:00 AM EDT - 4 weeks ago

Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026

2026-03-26T20:25:22.000Z - 6 weeks ago

Kyverna Therapeutics files $300M mixed securities shelf

2026-03-26T20:12:42.000Z - 6 weeks ago

Kyverna Therapeutics reports Q4 EPS (80c), consensus (86c)

Mar 26, 2026, 4:02 PM EDT - 6 weeks ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 9, 2026, 11:20 AM EDT - 2 months ago

Kyverna Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 5, 2026, 4:21 PM EST - 2 months ago

Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026

Mar 3, 2026, 8:00 AM EST - 2 months ago

Kyverna Therapeutics to Participate in Upcoming March Investor Conferences

2026-02-24T13:20:34.000Z - 2 months ago

Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board

BEAM

Feb 24, 2026, 8:00 AM EST - 2 months ago

Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

2026-02-03T13:25:38.000Z - 3 months ago

Kyverna Therapeutics appoints Pujols as Chief Technology Officer

Feb 3, 2026, 8:00 AM EST - 3 months ago

Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

Jan 14, 2026, 12:45 PM EST - 4 months ago

Kyverna Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-12T13:38:56.000Z - 4 months ago

Kyverna Therapeutics provides corporate update, priorities for 2026

Jan 12, 2026, 8:00 AM EST - 4 months ago

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:00 AM EST - 4 months ago

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

2025-12-17T14:30:20.000Z - 5 months ago

Kyverna prices 13.3M shares at $7.50 in underwritten public offering

Dec 17, 2025, 9:24 AM EST - 5 months ago

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

2025-12-16T11:51:24.000Z - 5 months ago

Kyverna Therapeutics price target raised to $33 from $31 at Wells Fargo

2025-12-15T21:05:21.000Z - 5 months ago

Kyverna Therapeutics offers to sell $100M in common stock

Dec 15, 2025, 4:01 PM EST - 5 months ago

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

2025-12-15T20:10:09.000Z - 5 months ago

Leerink raises Kyverna price target, says KYSA-8 study results transformative

2025-12-15T19:30:14.000Z - 5 months ago

Kyverna Therapeutics price target raised to $33 from $25 at Morgan Stanley

Dec 15, 2025, 8:00 AM EST - 5 months ago

Kyverna Therapeutics Transcript: Study Result

Dec 15, 2025, 6:42 AM EST - 5 months ago

Kyverna's cell therapy meets main goal of mid-stage study

Dec 15, 2025, 6:30 AM EST - 5 months ago

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Dec 14, 2025, 2:30 PM EST - 5 months ago

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

Nov 17, 2025, 8:00 AM EST - 6 months ago

Kyverna Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:05 PM EST - 6 months ago

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 6 months ago

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 3, 2025, 8:00 AM EST - 6 months ago

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

Oct 29, 2025, 8:00 AM EDT - 7 months ago

Kyverna Therapeutics Transcript: Study Update

Oct 29, 2025, 6:30 AM EDT - 7 months ago

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Oct 25, 2025, 11:00 AM EDT - 7 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

Oct 22, 2025, 8:00 AM EDT - 7 months ago

Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

Sep 24, 2025, 9:05 AM EDT - 8 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

Sep 15, 2025, 1:02 PM EDT - 8 months ago

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Sep 9, 2025, 11:00 AM EDT - 8 months ago

Kyverna Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 4:05 PM EDT - 8 months ago

Kyverna Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 11:00 AM EDT - 8 months ago

Kyverna Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 28, 2025, 11:00 AM EDT - 9 months ago

Kyverna Therapeutics Transcript: KOL Event

Aug 28, 2025, 8:00 AM EDT - 9 months ago

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Aug 25, 2025, 4:02 PM EDT - 9 months ago

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

Aug 12, 2025, 4:02 PM EDT - 9 months ago

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 8:30 AM EDT - 10 months ago

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

Jun 4, 2025, 4:55 PM EDT - 1 year ago

Kyverna Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

May 13, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Mar 27, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 10, 2025, 3:00 PM EDT - 1 year ago

Kyverna Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 3, 2025, 4:05 PM EST - 1 year ago

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Feb 7, 2025, 11:42 AM EST - 1 year ago

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

ak123456790 May. 13 at 7:34 AM

0 · Reply

Th3M4skedSt0nker May. 12 at 10:51 PM

$KYTX

0 · Reply

hummer2277 May. 12 at 10:26 PM

$KYTX more funds will start moving in as time goes on , buy and hold, already large institutional amount of investors.

0 · Reply

Salattis May. 12 at 8:12 PM

$KYTX https://www.globenewswire.com/news-release/2026/05/12/3293353/0/en/Kyverna-Therapeutics-Announces-Initiation-of-Rolling-SPS-BLA-Submission-and-Reports-First-Quarter-2026-Financial-Results.html

1 · Reply

AlphaOfBiotech May. 12 at 5:13 AM

1 · Reply

AlphaOfBiotech May. 12 at 3:51 AM

0 · Reply

InsaneZane May. 11 at 9:17 PM

$KYTX could this turn into a 2 day bull run?

0 · Reply

cb28 May. 11 at 6:09 PM

$KYTX why is this up today?

2 · Reply

peapope May. 11 at 3:07 PM

$KYTX first public Car-T to FDA approval!

0 · Reply

Th3M4skedSt0nker May. 11 at 2:50 PM

$KYTX I raise to $11 by end of this week 💲🔥💲🔥💲

0 · Reply

kellymone2 May. 11 at 2:42 PM

$KYTX As NTLA, KYTX is extremely undervalued. Soon it will jump

0 · Reply

peapope May. 11 at 2:41 PM

$KYTX

0 · Reply

Th3M4skedSt0nker May. 11 at 1:59 PM

$KYTX 5. Partnership or strategic interest hints This is where the speculative fireworks will happen. Big Pharma is aggressively moving into autoimmune and cell therapy: • $RHHBY • $BMY • $ABBV • Novartis • $GILD The entire sector is watching autoimmune CAR-T closely. Kyverna recently strengthened commercial leadership hiring ahead of launch preparation. A bullish earnings call could hint at: • strategic partnership discussions • manufacturing collaborations • commercialization support • regional licensing • or even inbound acquisition interest Even subtle language will ignite biotech momentum. 💲🔥💲🔥💲

0 · Reply

Th3M4skedSt0nker May. 11 at 1:56 PM

$KYTX 4. Manufacturing breakthrough / KYV-102 update One of the biggest challenges in CAR-T is manufacturing complexity and cost. Kyverna has discussed KYV-102 and a rapid whole-blood manufacturing process. Bull-case scenario: • improved turnaround time • outpatient treatment potential • scalable manufacturing update • lower cost of goods • increased manufacturing capacity This matters because investors want to know whether autoimmune CAR-T can become: • niche orphan treatment OR • scalable mainstream platform A convincing answer here will rerate the stock materially.

0 · Reply

Th3M4skedSt0nker May. 11 at 1:55 PM

$KYTX 3. Positive Multiple Sclerosis commentary This is the hidden upside. Kyverna has already hinted at encouraging IIT data in progressive MS. MS is an enormous market. If management says things like: • “transformational” • “functional recovery” • “expanded neuroimmunology strategy” • “registrational path discussions” the stock will react very aggressively because MS massively expands TAM (total addressable market). This is the type of surprise catalyst biotech momentum traders hunt for.

0 · Reply

Th3M4skedSt0nker May. 11 at 1:54 PM

$KYTX 2. Stronger durability data in gMG This may actually matter more long-term than SPS. The company has already shown extremely strong early gMG data: • deep responses • durable remission-like effects • potential elimination of chronic immunotherapy needs A bull-case earnings call could include: • additional patient follow-up • longer remission durability • steroid-free patients • faster symptom improvement • confirmation of favorable safety profile The market LOVES the phrase: “drug-free durable remission” because current autoimmune treatments are usually chronic and expensive lifelong therapies. If Kyverna demonstrates that one CAR-T treatment can replace years of biologics, investors may start modeling blockbuster revenue potential

0 · Reply

Th3M4skedSt0nker May. 11 at 1:52 PM

$KYTX Earnings on 13th, Wednesday - 5 Hot Scenarios which will make us fly - the more the merrier 💲🔥💲🔥💲🔥 1. Earlier-than-expected BLA timing for SPS This is probably the single biggest possible catalyst. Kyverna already guided toward a BLA submission for SPS in 1H 2026 and reported statistically significant registrational data. A major bullish surprise would be: • management implying FDA interactions are going exceptionally well • accelerated review potential • rolling submission language • priority review discussion • or confidence around commercial launch timing Why it matters: SPS has no approved therapies, which creates orphan-drug pricing power and potentially faster regulatory pathways. If investors begin viewing KYTX as the likely first approved autoimmune CAR-T company, valuation multiples will expand dramatically.

1 · Reply

michaftm May. 11 at 11:56 AM

$UNCY tic tac ⏳️ still a few weeks to get in, then it ll be too late. FDA approval 29th of june 🚀 Favorite bio with $KYTX & $IBRX

1 · Reply

Fosco_ May. 11 at 10:53 AM

$IMMX $KYTX Bringing this back to the top for more visibility: In response to @Surfho’s preference for KYTX, I’ve outlined quickly in the pdf link my investment thesis on why I think IMMX offers a better setup . Both very good plays IMO btw.

1 · Reply

InsaneZane May. 9 at 2:22 PM

$KYTX what are we thinking for next week? Will we see this thing back in the 11s?

1 · Reply

Th3M4skedSt0nker May. 8 at 12:17 AM

$KYTX RFG Advisory LLC bought 445,200 shares of Kyverna Therapeutics (NASDAQ:KYTX) in Q4, a stake valued at about $4.19 million representing roughly 1.02% ownership. Other institutional activity included AIGH Capital's new ~$14.1 million position, and institutional/hedge funds now own about 18.08% of the company, signaling notable investor interest.

0 · Reply

Jekky May. 7 at 3:20 PM

$KYTX

0 · Reply

Market Cap	625.88M
Revenue (ttm)	0.00
Net Income (ttm)	-161.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.11

Volume	616,100
Avg Vol	920,956
Day's Range	N/A - N/A
Shares Out	60.53M
Stochastic %K	78%
Beta	2.05
Analysts	Strong Sell
Price Target	$29.60